Ted Davis to Succeed Amy Tseng as President and CEO of TissueTech

Jan 27 2022

MIAMI—(BUSINESS WIRE)—TissueTech, Inc., a pioneer in the clinical application of cryopreserved human birth tissue products to treat ocular surface disease and disorders, chronic wounds, and musculoskeletal conditions, has named Ted Davis as the company’s new president and CEO. Davis—a seasoned biologics and orthopedics executive—takes the helm of an emerging company experiencing exponential growth, succeeding TissueTech founder and former CEO Amy Tseng, who retired January 3. Tseng remains a member of the company’s board of directors.

“It is an honor to be only the second CEO in TissueTech’s 25-year history. I have watched the company for more than a decade and have been impressed with its platform technology, clinical outcomes, and surgeon support,” said Davis. “With the addition of ongoing clinical programs to secure biologics license applications for indications to address significant unmet clinical needs in the ophthalmology, orthopedics, and wound management segments, TissueTech is poised to secure its position as a leader in regenerative medicine—now and into the future.”

Davis most recently served for five years as president and CEO of Active Implants, LLC, a medical device company focused on the knee preservation segment of sports medicine. He began his career with a decade in the life sciences venture capital field, then transitioned into operating leadership roles at Wright Medical Technology and MicroPort Orthopedics before joining Active Implants, where he is still on the board of directors. Davis also currently serves on the boards of Axis Spine Technologies, Ltd. and SIbone, Inc.

“On behalf of the board, I welcome Ted to TissueTech,” said Robert White, chairman of TissueTech and an operating partner at EW Healthcare. “His experience in strategic business development across the biologics, orthopedics, and life sciences sectors will be instrumental as we transform from a tissue-based manufacturer to a biologics therapy provider. We’re excited about what’s ahead.”

Since its inception in 1997, TissueTech has pioneered the clinical application of human placental tissues. Today, more than 600,000 patients have been treated with TissueTech products and the company’s groundbreaking scientific and clinical achievements have been documented in more than 300 peer-reviewed publications.

“Amy’s contributions to TissueTech over the past 25 years—and the resulting impact on the patients we treat—cannot be overstated,” said White. “We are beyond thankful for her extraordinary leadership, and look forward to continuing to work together in her role as a member of our board of directors.”

“I’m proud of what we have built at TissueTech, and I believe in our future as a biologics company,” said Amy Tseng. “For more than two decades, co-founder Dr. Scheffer Tseng and I have led the continuous innovation behind the use of birth tissue products to treat many different diseases, and persevered in the development of the leading amniotic membrane technology platform in regenerative medicine.”

“I want to thank the board and my colleagues for their partnership in building a strong foundation at TissueTech,” Tseng continued. “I am pleased to transition leadership of the organization to Ted, as I know he will bring new energy, experience and ideas to this next phase of growth for TissueTech.”

About TissueTech, Inc.

TissueTech, Inc. is an emerging biotechnology company and leader in regenerative medicine using human birth tissue. TissueTech’s pioneering amniotic membrane products are processed using its proprietary CRYOTEK® cryopreservation technology, designed to retain the tissue’s structural and functional integrity. Today, TissueTech is breaking new ground with multiple Investigational New Drug clinical trials underway as the company pursues 351 biologics’ approval for products to treat patients’ unmet clinical needs. TissueTech is committed to empowering healthcare professionals with solutions to deliver optimal patient outcomes by fostering innovation through evidence-based science. Since its inception, clinicians have performed over 600,000 human implants with its products and published over 380 peer-reviewed studies supporting TissueTech’s platform technology. Learn more at


Media Contact
Heather Kowalczyk, APR
McDougall Communications for TissueTech, Inc.
[email protected] or (585) 434-2148